Deals

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy
Hiteck Biological PharmaSHE: 300683

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy

Wuhan Hiteck Biological Pharma Co., Ltd. (SHE: 300683) announced that it has signed an exclusive collaboration and licensing agreement with Visara, Inc., a U.S. clinical‑stage biopharmaceutical company focused on innovative…

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative
Academic conferenceBoehringer Ingelheim

Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders
Academic conferenceEisai

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders

Sichuan Biokin Launches on HKEX, Raises HK$3.3 B in $389/Share Offering – A Milestone for China’s Biotech
Biokin PharmaceuticalIPO

Sichuan Biokin Launches on HKEX, Raises HK$3.3 B in $389/Share Offering – A Milestone for China’s Biotech

AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal
AmacaTheraBiotech

AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal

Show More